Oral composition, and method for suppressing bitterness originating from ergothioneine or salt thereof and odor originating from chondroitin sulfate or salt thereof

MYPI2025000468A0Undetermined Publication Date: 2024-01-19SUNTORY HLDG LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000468
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-19
Filing Date
2023-07-12
Publication Date
2024-01-19

AI Technical Summary

Technical Problem

Ergothioneine and chondroitin sulfate, despite their physiological benefits, pose challenges due to a bitter taste and fishy odor, respectively, making their incorporation into oral compositions undesirable.

Method used

Combining ergothioneine or its salt with chondroitin sulfate or its salt in a specific weight ratio of 2 to 60, effectively suppressing the bitterness and odor, thereby enhancing the palatability of oral compositions.

Benefits of technology

The method allows for the continuous intake of ergothioneine and chondroitin sulfate by reducing their bitter taste and odor, making them more acceptable in oral formulations, while maintaining their health benefits.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention aims to provide an oral composition containing ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof, wherein the bitterness derived from the ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof are suppressed. The present invention relates to an oral composition containing a component (A) and a component (B) defined as follows: (A) ergothioneine or a salt thereof; and (B) chondroitin sulfate or a salt thereof, wherein a (B) / (A) weight ratio of the component (B) in terms of chondroitin sulfate to the component (A) in terms of ergothioneine is 2 to 60.
Need to check novelty before this filing date? Find Prior Art

Description

Oral composition and method for suppressing bitterness derived from ergothioneine or its salt and odor derived from chondroitin sulfate or its salt

[0001] The present invention relates to an oral composition containing ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof. The present invention also relates to a method for suppressing the bitterness derived from ergothioneine and the odor derived from chondroitin sulfate or a salt thereof.

[0002] Ergothioneine is a hydrophilic sulfur-containing amino acid known to have various physiological activities, including antioxidant activity. Regarding the physiological activities of ergothioneine, for example, Patent Document 1 reports that it has the effect of activating immune responses and promoting cytokine production. Due to its diverse physiological activities, ergothioneine has recently attracted attention for use in foods, cosmetics, and pharmaceuticals.

[0003] Chondroitin sulfate is a type of acidic mucopolysaccharide that exists in animal bodies as a proteoglycan covalently bound to a core protein, usually called a core protein. Chondroitin sulfate is present in many animal tissues, including cartilage, connective tissues such as skin, and brain tissue. It is particularly abundant in the extracellular matrix of cartilage, and is used in health foods to improve symptoms such as osteoarthritis.

[0004] Japanese Patent Application Laid-Open No. 2017-218431

[0005] As described above, ergothioneine has useful physiological activities, and therefore foods such as supplements containing ergothioneine or its salts are useful for maintaining or improving health. However, ergothioneine or its salts have a unique flavor, particularly a stinging bitter taste, which leaves room for improvement when used in oral compositions. In addition, chondroitin sulfate has a fishy odor, which can be problematic when incorporated into oral compositions.

[0006] An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof, in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof are suppressed. Another object of the present invention is to provide a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof.

[0007] As a result of intensive research conducted by the present inventors to solve the above-mentioned problems, they found that the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof can be suppressed by combining ergothioneine or a salt thereof with chondroitin sulfate or a salt thereof in a specific ratio.

[0008] The present invention includes the following compositions, etc.: [1] An oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, wherein the weight ratio ((B) / (A)) of component (B) (in terms of chondroitin sulfate) to component (A) (in terms of ergothioneine) is 2 to 60. [2] The composition according to the above item [1], which is a food or drink. [3] A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof in an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, by adjusting the weight ratio ((B) / (A)) of component (B) (in terms of chondroitin sulfate) to component (A) (in terms of ergothioneine) to be 2 to 60.

[0009] According to the present invention, an oral composition containing ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof and having a suppressed bitterness derived from ergothioneine or a salt thereof and a suppressed odor derived from chondroitin sulfate or a salt thereof can be provided. Furthermore, according to the present invention, a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the suppressed odor derived from chondroitin sulfate or a salt thereof can be provided.

[0010] The oral composition of the present invention contains (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, and the weight ratio ((B) / (A)) of component (B) (in terms of chondroitin sulfate) to component (A) (in terms of ergothioneine) is 2 to 60.

[0011] Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and may be either an acid salt or a basic salt. Examples of acid salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.

[0012] Ergothioneine or a salt thereof is not limited in any way by its form, production method, etc. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from a natural product. L-ergothioneine is contained in large amounts in the Golden / Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom of the Pleurotus genus in the family Pleurotus. L-ergothioneine is found in mushrooms such as white button mushrooms, crimini mushrooms, and portabella mushrooms (Agaricus bisporus), Grey Oyster Mushrooms (Pleurotus ostreatus), shiitake mushrooms (Lentinula edodes), Maitake mushrooms (Grifola frondosa), reishi mushrooms (Ganoderma lucidum), Yamabushitake mushrooms (Hericium erinaceus), Yanagimatsutake mushrooms (Agrocybe aegerita), and chanterelle mushrooms (Cantharella verruca). It is also contained in mushrooms such as mushrooms such as Pleurotus cibarius, porcini mushroom (scientific name: Boletus edulis), and morel mushroom (scientific name: Morchella esculenta). When obtaining L-ergothioneine from a natural product, it is preferably extracted from Pleurotus cornucopiae. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.

[0013] Chondroitin sulfate is an acidic mucopolysaccharide having a repeating disaccharide structure in which D-glucuronic acid or its epimer is bound to N-acetyl-D-galactosamine, and at least some of the hydroxyl groups in the D-glucuronic acid or its epimer and N-acetyl-D-galactosamine are sulfated. Examples of epimers of D-glucuronic acid include iduronic acid, which is an epimer of C5. The chondroitin sulfate is not particularly limited, and examples thereof include chondroitin sulfate A having a structural unit derived from glucuronic acid and a structural unit derived from N-acetylgalactosamine 4sulfate; chondroitin sulfate B having a structural unit derived from iduronic acid disulfate and a structural unit derived from N-acetylgalactosamine 4sulfate; chondroitin sulfate C having a structural unit derived from glucuronic acid and a structural unit derived from N-acetylgalactosamine hexasulfate; chondroitin sulfate D having a structural unit derived from glucuronic acid disulfate and a structural unit derived from N-acetylgalactosamine hexasulfate; chondroitin sulfate E having a structural unit derived from glucuronic acid and a structural unit derived from N-acetylgalactosamine 4,6-disulfate; chondroitin sulfate H having a structural unit derived from iduronic acid trisulfate and a structural unit derived from N-acetylgalactosamine 4sulfate; and chondroitin sulfate K having a structural unit derived from glucuronic acid disulfate and a structural unit derived from N-acetylgalactosamine 4,6-disulfate. In one preferred embodiment of the present invention, the chondroitin sulfate is at least one selected from the group consisting of chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, chondroitin sulfate D, chondroitin sulfate E, chondroitin sulfate H, and chondroitin sulfate K.

[0014] Chondroitin sulfate has a fishy odor. By containing chondroitin sulfate or a salt thereof, the composition of the present invention reduces the bitterness derived from ergothioneine or a salt thereof. By combining chondroitin sulfate or a salt thereof with ergothioneine or a salt thereof, the odor derived from chondroitin sulfate or a salt thereof can also be suppressed. This makes it easy to continuously ingest ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof.

[0015] The salt of chondroitin sulfate is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and examples thereof include alkali metal salts such as sodium and potassium; alkaline earth metal salts such as calcium and magnesium; etc. Alkali metal salts are preferred, and sodium salts are more preferred.

[0016] The chondroitin sulfate and its salts used in the present invention are not limited in any way by their form or production method, and may be commercially available products or products extracted and purified from natural products. For example, chondroitin sulfate can be obtained by a method of extracting chondroitin sulfate from cartilage of cartilaginous fish such as sharks, bony fish such as salmon and trout, mollusks such as squid, or animal cartilage such as cows, pigs, and chickens.

[0017] In the composition of the present invention, the weight ratio of component (B) (in terms of chondroitin sulfate) to component (A) (in terms of ergothioneine) ((B) in terms of chondroitin sulfate / (A) in terms of ergothioneine) is 2 to 60. Ergothioneine or a salt thereof has a bitter taste that stings the tongue. Chondroitin sulfate or a salt thereof also has an odor. In a composition containing components (A) and (B), when the weight ratio ((B) / (A)) of component (B) (in terms of chondroitin sulfate) to component (A) (in terms of ergothioneine) is within the above range, the bitterness derived from component (A) can be suppressed, and the odor derived from component (B) can also be suppressed. This facilitates continuous intake of ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof. The weight ratio ((B) / (A)) is preferably 3 to 55, more preferably 4 to 50, even more preferably 5 to 45, particularly preferably 6 to 40, and most preferably 7 to 35.

[0018] The content of ergothioneine or a salt thereof in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of ergothioneine or a salt thereof in the composition of the present invention, in terms of ergothioneine, is, for example, preferably 0.05% by weight or more, more preferably 0.1% by weight or more, even more preferably 0.5% by weight or more, even more preferably 0.6% by weight or more, even more preferably 0.8% by weight or more, particularly preferably 1% by weight or more, and preferably 30% by weight or less, more preferably 20% by weight or less, and even more preferably 10% by weight or less. In one aspect, the content of ergothioneine or a salt thereof in the composition of the present invention, in terms of ergothioneine, is preferably 0.05 to 30% by weight, more preferably 0.1 to 30% by weight, more preferably 0.5 to 30% by weight, even more preferably 0.6 to 20% by weight, even more preferably 0.8 to 20% by weight, and particularly preferably 1 to 10% by weight. When the composition of the present invention contains two or more compounds as ergothioneine or a salt thereof, the content of ergothioneine or a salt thereof refers to the total content thereof. The ergothioneine content can be measured by high-performance liquid chromatography (HPLC). The amount of ergothioneine or a salt thereof converted into ergothioneine or a similar expression refers to the amount of ergothioneine in the case of ergothioneine. In the case of a salt of ergothioneine, it refers to the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.

[0019] The content of chondroitin sulfate or a salt thereof in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of chondroitin sulfate or a salt thereof in the composition of the present invention, calculated as chondroitin sulfate, is, for example, preferably 0.1% by weight or more, more preferably 0.2% by weight or more, even more preferably 1% by weight or more, and preferably 99% by weight or less, more preferably 98% by weight or less, even more preferably 95% by weight or less, even more preferably 90% by weight or less, and particularly preferably 85% by weight or less. In one aspect, the content of chondroitin sulfate or a salt thereof in the composition of the present invention, calculated as chondroitin sulfate, is preferably 0.1 to 99% by weight, more preferably 0.2 to 98% by weight, even more preferably 0.2 to 95% by weight, even more preferably 1 to 90% by weight, and particularly preferably 1 to 85% by weight. In one embodiment, the content of chondroitin sulfate or a salt thereof may be 0.2 to 50 wt%, 0.4 to 40 wt%, 0.5 to 30 wt%, 0.8 to 20 wt%, or 1 to 10 wt% in terms of chondroitin sulfate. When the composition of the present invention contains two or more compounds as chondroitin sulfate or a salt thereof, the content of chondroitin sulfate or a salt thereof refers to the total content thereof. The content of chondroitin sulfate or a salt thereof can be measured by HPLC. When the amount of chondroitin sulfate or a salt thereof in terms of chondroitin sulfate or a similar expression is used, it means the amount in terms of chondroitin sulfate. In the case of a chondroitin sulfate salt, it means the value obtained by multiplying the number of moles of the salt by the molecular weight of chondroitin sulfate.

[0020] The composition of the present invention preferably contains 1 to 100 mg of ergothioneine or a salt thereof, per daily intake for an adult, in ergothioneine equivalent, more preferably 2 to 50 mg, even more preferably 5 to 25 mg, and particularly preferably 5 to 20 mg. The composition of the present invention preferably contains 2 to 200 mg of chondroitin sulfate or a salt thereof, per daily intake for an adult, in chondroitin sulfate equivalent, more preferably 4 to 150 mg, and even more preferably 5 to 100 mg.

[0021] Ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof are compounds contained in natural products and foods and beverages, and are commonly consumed. Therefore, from the viewpoint of safety, it is believed that ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof pose few problems even when ingested daily. According to the present invention, it is possible to provide a composition that is highly safe and easy to ingest, with reduced bitterness derived from ergothioneine or a salt thereof and reduced odor derived from chondroitin sulfate or a salt thereof.

[0022] As described above, ergothioneine or a salt thereof is known to exhibit a variety of physiological activities and health functions, such as antioxidant activity, brain function improving effect, anti-aging effect, eye disease improving effect, whitening effect, ultraviolet absorption effect, melanin production suppression effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation suppression effect, skin sagging suppression effect, autophagy promotion effect, etc. Therefore, the composition of the present invention can be suitably used for antioxidant activity, brain function improving effect, anti-aging effect, eye disease, whitening effect, ultraviolet absorption effect, melanin production suppression, reactive oxygen species scavenging effect, elastase activity inhibition effect, wrinkle formation suppression effect, skin sagging suppression effect, autophagy promotion effect, etc.

[0023] Chondroitin sulfate or a salt thereof is known to exhibit health benefits such as alleviating pain from osteoarthritis of the knee, osteoarthritis of the hip, etc. Since the composition of the present invention contains chondroitin sulfate or a salt thereof, it can also be used to obtain the above-mentioned effects exerted by these.

[0024] The composition of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes. Non-therapeutic is a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis. The composition of the present invention can be in the form of a food or beverage, a pharmaceutical product, a quasi-drug, a feed, or the like. The composition of the present invention may be a material or a preparation to be incorporated into a food or beverage, a pharmaceutical product, a quasi-drug, a feed, or the like.

[0025] The composition of the present invention is an oral composition, and specific examples of oral compositions include foods and beverages, oral medicines, quasi-drugs, feeds, etc., preferably foods and beverages or oral medicines, more preferably foods and beverages.

[0026] The composition of the present invention may contain any additives and any components in addition to ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof, as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, and those generally usable for oral compositions such as foods and beverages, pharmaceuticals, quasi-drugs, and feeds can be used. When the composition of the present invention is used as a food or beverage, pharmaceutical, quasi-drug, feed, or the like, the method for producing the composition is not particularly limited, and the composition can be produced by a general method. In one embodiment, the composition of the present invention may consist of ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof. The form of the oral composition of the present invention is not particularly limited, and may be a solid (powder, granules, tablet, etc.), liquid, paste, etc.

[0027] For example, when the composition of the present invention is used as a food or beverage, various foods and beverages can be prepared by blending ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof with ingredients that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.). The foods and beverages are not particularly limited, and examples include general foods and beverages, health foods, health supplements, health drinks, functional foods, foods for specified health uses, and foods and beverages for patients. The health foods, health supplements, functional foods, foods for specified health uses, etc. can be used in various dosage forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.

[0028] When the composition of the present invention is used as a pharmaceutical or quasi-drug, for example, ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof may be combined with a pharmacologically acceptable carrier, additives added as needed, and the like to produce a pharmaceutical or quasi-drug in various dosage forms. Such carriers, additives, and the like may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, and the like. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, and the like.

[0029] When the composition of the present invention is used as a feed, ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof may be blended into the feed. The feed also includes feed additives. Examples of the feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.

[0030] The subject to which the composition of the present invention is ingested or administered (also referred to as the administration subject) is not particularly limited, and is preferably a human or a non-human mammal, more preferably a human.

[0031] The present invention also encompasses the following method: A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof in an oral composition containing (A) ergothioneine or a salt thereof and (B) chondroitin sulfate or a salt thereof, by adjusting the weight ratio ((B) / (A)) of component (B) (in chondroitin sulfate equivalent) to component (A) (in ergothioneine equivalent) to 2 to 60. By adjusting the weight ratio ((B) / (A)) of component (B) (in chondroitin sulfate equivalent) to component (A) (in ergothioneine equivalent) to fall within the above range in the preparation of the oral composition, an oral composition can be obtained in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof are suppressed.

[0032] The above method makes it possible to effectively suppress the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof. The taste of the oral composition can be improved by suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof. In the above method, ergothioneine or a salt thereof, chondroitin sulfate or a salt thereof, and preferred embodiments thereof are the same as those in the oral composition of the present invention described above. The preferred range of the weight ratio ((B) / (A)) of component (B) (in terms of chondroitin sulfate) to component (A) (in terms of ergothioneine) is also the same as that in the oral composition of the present invention.

[0033] The bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof can be suppressed by the above-mentioned method, but other methods for suppressing these unpleasant flavors may be combined. Examples of other suppression methods include a method of adding a sweetener or a flavoring agent to a component having such an unpleasant flavor to prepare a formulation, a method of coating the component with a sugar coating to prepare a formulation, or a method of encapsulating the component to prepare a formulation.

[0034] Chondroitin sulfate or a salt thereof is useful for suppressing the bitterness of ergothioneine or a salt thereof. The present invention also encompasses the use of (B) chondroitin sulfate or a salt thereof for suppressing the bitterness derived from (A) ergothioneine or a salt thereof. The amount of chondroitin sulfate or a salt thereof used is preferably such that the weight ratio ((B) / (A)) of (B) chondroitin sulfate or a salt thereof (converted to chondroitin sulfate) to (A) ergothioneine or a salt thereof (converted to ergothioneine) is 2 or more, and more preferably such that the weight ratio is 2 to 60.

[0035] Ergothioneine or a salt thereof is useful for suppressing the odor of chondroitin sulfate or a salt thereof. The present invention also encompasses the use of (A) ergothioneine or a salt thereof for suppressing the odor derived from (B) chondroitin sulfate or a salt thereof. The amount of ergothioneine or a salt thereof used is preferably such that the weight ratio ((B) / (A)) of (A) ergothioneine or a salt thereof (in ergothioneine equivalent) to (B) chondroitin sulfate or a salt thereof (in chondroitin sulfate equivalent) is 2 or more, and more preferably such that the weight ratio is 2 to 60.

[0036] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.

[0037] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.

[0038] The materials used in the following evaluation tests are as follows: (A) Ergothioneine: raw material containing 100% L-ergothioneine (B) Chondroitin sulfate: raw material containing 70% shark-derived chondroitin sulfate

[0039] Example 1: Flavor Evaluation Test for Compositions Containing Ergothioneine and Chondroitin Sulfate Compositions containing ergothioneine and chondroitin sulfate were prepared, and three panelists skilled in sensory evaluation performed sensory evaluations. The amounts of (A) and (B) shown in Table 1 were mixed to prepare compositions of Samples 1 to 6 (compositions containing ergothioneine and chondroitin sulfate). The weight ratios of (B) / (A) in the compositions of Samples 1 to 6 ((B) / (A) in terms of chondroitin sulfate) are shown in Table 1. Each of the three panelists placed the entire amount of the prepared composition (for example, 20 mg in total, consisting of 10 mg of (A) and 10 mg of (B) for Sample 1) directly on their tongues, and evaluated the intensity of the bitterness derived from ergothioneine and the intensity of the odor derived from chondroitin sulfate according to the following criteria.

[0040] (A) Evaluation criteria for bitterness derived from ergothioneine The intensity of the bitterness of (A) alone (10 mg) was assigned 5 points (control 1), and 1 point was assigned to the case where no bitterness derived from ergothioneine was felt, and the samples were evaluated on a 5-point scale from 1 to 5 points. The evaluations of three panelists were compiled, and the average values ​​are shown in Table 1. 5 points: Strong bitterness derived from ergothioneine felt 4 points: Bitterness derived from ergothioneine felt 3 points: Slight bitterness derived from ergothioneine felt 2 points: Little bitterness derived from ergothioneine felt 1 point: No bitterness derived from ergothioneine felt

[0041] (B) Evaluation criteria for odor derived from chondroitin sulfate The odor intensity of (B) alone (10 mg) was assigned 5 points (Control 2), and no odor derived from chondroitin sulfate was assigned 1 point, and the evaluation was performed on a 5-point scale from 1 to 5 points (5 levels). The evaluations of three panelists were compiled, and the average values ​​are shown in Table 1. 5 points: Strong odor derived from chondroitin sulfate 4 points: Odor derived from chondroitin sulfate 3 points: Slight odor derived from chondroitin sulfate 2 points: Little odor derived from chondroitin sulfate 1 point: No odor derived from chondroitin sulfate

[0042] When the average scores for the evaluation of the bitterness derived from ergothioneine and the evaluation of the odor derived from chondroitin sulfate were both less than 4.0 points, it was evaluated that the bitterness derived from ergothioneine and the odor derived from chondroitin sulfate were suppressed.

[0043]

[0044] When chondroitin sulfate was not added, the stinging bitterness derived from ergothioneine was strongly felt (Control 1). On the other hand, when chondroitin sulfate alone was added, the odor derived from chondroitin sulfate was strongly felt (Control 2). In Samples 2 to 4 and Sample 6, in which the weight ratio of (B) chondroitin sulfate to (A) ergothioneine ((B) / (A)) was in the range of 2 to 60, both the bitterness derived from ergothioneine and the odor derived from chondroitin sulfate were effectively alleviated.

Claims

1. An oral composition comprising the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, wherein the weight ratio ((B) / (A)) of component (B) (converted to chondroitin sulfate) to component (A) (converted to ergothioneine) is 2 to 60.

2. The composition according to claim 1, which is a food or drink.

3. A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from chondroitin sulfate or a salt thereof in an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, by adjusting the weight ratio ((B) / (A)) of component (B) (converted to chondroitin sulfate) to component (A) (converted to ergothioneine) to be 2 to 60.